Here are the 424B prospectus supplements from Niki BioSolutions, Inc. (NIKI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NIKI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NIKI filings page.
Niki BioSolutions, Inc. (NIKI) may offer and sell common stock with an aggregate offering price of up to $1,396,000 through an at-the-market program from time to time, with H.C. Wainwright & Co., LLC acting as selling manager. The company is not assured of selling any shares.
Sales compensation is set at 3.0% of gross proceeds. Niki intends to use net proceeds, if any, for general corporate purposes, including working capital, product development, and sales and marketing. Under the prospectus’s illustration of 330,023 shares sold at $4.23 per share, new purchasers would face immediate net tangible book value dilution of $(0.89) per share; existing shareholders’ net tangible book value would decrease by $(0.12) per share.
Niki reported 2,938,625 shares outstanding as of October 8, 2026. The prospectus identifies regulatory uncertainty related to Hong Kong as a potential risk to operations and securities value and says Niki does not expect to pay cash dividends in the foreseeable future.